CSF1R and sarcoma: A recent preclinical study on the CSF-1/CSF-1R inhibitor pexidartinib in the treatment of sarcoma demonstrated that, in addition to decreasing TAM infiltration and phenotypic changes from M2 to M1, increased CD8+T cell infiltration and decreased Treg cell infiltration were observed in the TME post-treatment.